Study to evaluate safety, tolerability and effects on blood pressure of CERC-301 in patients with nOH
BALTIMORE, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), today announced that it has enrolled the first patient in a Phase I study of its proprietary drug candidate CERC-301 in patients with neurogenic Orthostatic Hypotension (nOH) associated with Parkinson’s disease. The study will evaluate the single-dose safety, tolerability and pharmacokinetics of CERC-301 in this patient population, as well as explore the effects on blood pressure and symptoms of nOH during an orthostatic challenge at escalating dose levels.
Peter Greenleaf, Chief Executive Officer of Cerecor, commented, "With the first patient enrolled in our Phase I trial, we are now actively studying CERC-301 in nOH. We are excited about the progress that our team has made in advancing the clinical development of CERC-301, which demonstrates the potential of our pipeline. We are transforming Cerecor into a fully integrated innovation driven Specialty Pharmaceutical Company. Our intent is to leverage the profits of our commercial portfolio as fuel for innovation to support our clinical development programs.”
Dr. Stuart Isaacson, Director, Parkinson’s Disease and Movement Disorders Center of Boca Raton, Associate Professor of Neurology, Herbert Wertheim College of Medicine and lead investigator for the study, commented, “We are extremely excited about this compound. There is a substantial unmet need in this area for Parkinson’s patients. What we like about the compound is that it’s previously been evaluated in patients with Parkinson’s and though small numbers, we have not seen any serious adverse events, so we hope it will be safe and well tolerated and offer a new option into the management of nOH in patients with Parkinson’s Disease as it progresses in its evaluation.”
nOH is an orphan disease resulting from failure of the autonomic nervous system to regulate blood pressure in response to postural change, due to an inadequate release of norepinephrine. nOH is observed in several neurodegenerative diseases, including Parkinson’s disease (PD), multiple systems atrophy, primary autonomic failure, and non-diabetic autonomic neuropathy. The Company believes that nOH constitutes an area in which there is still significant unmet medical need.
Current treatment options for nOH target symptom burden reductions to increase quality of life such as correcting aggravating factors (i.e. discontinuation of hypotension drugs and correction of anemia and vitamin deficiencies); nonpharmacologic measures such as intravascular volume expansion, increased physical activity, reduction of meal size, compression stocking/abdominal binder, and sleeping arrangement; and drug therapies (i.e. droxidopa, midrodrine, fludrocortisone, pyridostigmine, atomoxetine).
About the nOH Study
This is a single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of CERC-301 in patients with symptomatic nOH associated with Parkinson's disease. This is a multi-center study in the United States, with data expected in the first half of 2019.